Harnessing the Power of Targeting c-Kit

Who We Are

Jasper is a biotechnology company focused on enabling cures by targeting mast cells and stem cells.

Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, safer and more effective conditioning for monogenetic diseases and new engineered stem cell therapies.

Learn More

Our Targeted Anti c-Kit Antibody

Briquilimab (formerly JSP191) is a targeted anti c-Kit monoclonal antibody designed to deplete diseased mast and stem cells as well as enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.

Jasper is studying briquilimab across multiple diseases. Briquilimab is currently being studied as a targeted conditioning agent for severe combined immunodeficiency (SCID), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Fanconi Anemia (FA) and Sickle Cell Disease (SCD). Jasper will also be starting studies of briquilimab as a chronic therapeutic in patients with Chronic Urticaria and Low to Intermediate Risk MDS.

Learn More

Our Cellular
Engineering Platform

Jasper’s Engineered Hematopoietic Stem Cells (mRNA Stem Cell Grafts) are designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.

By using mRNA or DNA editing, Jasper can give the modified donor or autologous stem cells a proliferative and survival advantage (transient or permanent) over the patient’s existing stem cells. Ultimately, our aim is to achieve superior engraftment leading to higher percentages of therapeutic transplants and more effective gene therapies. Furthermore, mRNA Stem Cell Grafts may expand the potential for off the shelf transplants while removing the risk of GVHD and reducing or eliminating the need for toxic conditioning compared to current standard of care therapies.

Learn More

Leadership Team

Jasper Therapeutics’ management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization.

With this leadership, we are well positioned to achieve our vision of increasing cure rates of allogeneic and gene therapy grafts while significantly expanding the eligible patient population.

Learn More